Cargando…
Prolonged extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome in a child affected by rituximab-resistant autoimmune hemolytic anemia: a case report
INTRODUCTION: Autoimmune hemolytic anemia in children younger than 2 years of age is usually characterized by a severe course, with a mortality rate of approximately 10%. The prolonged immunosuppression following specific treatment may be associated with a high risk of developing severe infections....
Autores principales: | Beretta, Chiara, Leoni, Veronica, Rossi, Mario Renato, Jankovic, Momcilo, Patroniti, Nicolo, Foti, Giuseppe, Biagi, Ettore |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726476/ https://www.ncbi.nlm.nih.gov/pubmed/19830103 http://dx.doi.org/10.1186/1752-1947-3-6443 |
Ejemplares similares
-
Cold autoimmune hemolytic anemia resolved by rituximab
por: Palombi, Massimiliano, et al.
Publicado: (2010) -
Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia
por: Murakhovskaya, Irina
Publicado: (2020) -
Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
por: Fozza, Claudio, et al.
Publicado: (2011) -
Erythrodermic Psoriasis after Rituximab Treatment in a Patient with Autoimmune Hemolytic Anemia
por: Koumaki, Dimitra, et al.
Publicado: (2021) -
Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia
por: Yao, Mingkang, et al.
Publicado: (2022)